Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The study will include 100 women with unexplained recurrent implantation failure undergoing
IVF/ICSI cycle.
Patients fulfilling the inclusion criteria will be randomised into two groups.
Study Group:
This group will include 50 women with unexplained recurrent implantation failure undergoing a
trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20%, on the day
of oocyte retrieval, a second dose on/ the following day of positive pregnancy test and a
final dose 2-3 weeks later when attending for pregnancy scan.
Control Group:
This group will include 50 women with unexplained recurrent implantation failure undergoing a
trial of IVF/ICSI. This group will receive intravenous infusion of placebo, on the day of
oocyte retrieval, a second dose on/ the following day of positive pregnancy test and a final
dose 2-3 weeks later when attending for pregnancy scan.